Intersect ENT Inc

Intersect ENT — Technical Presentation (September 2017)

16 slides from Intersect ENT's technical presentation, Sep 11, 2017

  1. Slide 1: Study of corticosteroid-eluting implants as an alternative to revision surgery: a meta-analysis

    Study of corticosteroid-eluting implants placed in-office as an alternative to revision surgery in patients with recurrent sinus obstruction due to polyposis: a meta-analysis J. Pablo Stolovitzky, MD, Atlanta, GA Robert L. Kern, MD, Chicago, IL Joseph K. Han, MD, Norfolk, VA Keith D. Forwith, PhD, M

  2. Slide 2: Disclosures

    Disclosures Presenter Disclosures: J. Pablo Stolovitzky: Consultant intersect ENT Robert Kern: None Joseph Han: Consultant intersect ENT Keith Forwith : None Randall Ow: None Andrew Gould: None The steroid-releasing implant discussed in this presentation is not approved by the US FDA. The implant is

  3. Slide 3: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) • The multi-factorial pathophysiology of CRSwNP prevents long-term effectiveness of any single treatment option • Medical management includes systemic and intranasal corticosteroids (INCS) • Surgical treatment relieves blockage and improves ventilati

  4. Slide 4: Investigational Office-based Therapy Designed for Nasal Polyps in CRS Patients

    Investigational Office-based Therapy Designed for Nasal Polyps in CRS Patients An investigational corticosteroid-eluting, bioabsorbable sinus implant designed to provide localized delivery of 1350 mcg of mometasone furoate over 90 days Steroid releasing implant discussed is not approved by the FDA.

  5. Slide 5: Two Randomized Controlled Trials

    Two Randomized Controlled Trials RESOLVE RESOLVE II N=100 N=300 • Randomized 1:1 • Randomized 2:1 • Sham-controlled • Sham-controlled • Double-blind • Double-blind • 6 months follow-up • 3 months follow-up Treatment Group: in-office bilateral implant placement in the ethmoid sinuses + MFNS 200 mcg Q

  6. Slide 6: Investigational Sinus Implant for In-Office Treatment of Nasal Polyps

    Investigational Sinus Implant for In-Office Treatment of Nasal Polyps Steroid releasing implant discussed is not approved by the FDA. The product is an investigational drug not currently available for sale in the United States. The steroid releasing implants are limited by federal (or United States)

  7. Slide 7: Meta-Analysis

    Meta-Analysis RESOLVE RESOLVE II N=100 N=300 • Randomized 1:1 • Randomized 2:1 • Sham-controlled • Sham-controlled • Double-blind • Double-blind • 6-month follow-up • 3-month follow-up Meta-Analysis N=400 90 Day Results Steroid releasing implant discussed is not approved by the FDA. The product is a

  8. Slide 8: Objective of Meta-Analysis

    Objective of Meta-Analysis To evaluate the sinus implant in patients with recurrent and medically refractory nasal polyps Steroid releasing implant discussed is not approved by the FDA. The product is an investigational drug not currently available for sale in the United States. The steroid releasin

  9. Slide 9: Meta-Analysis Co-primary Efficacy Endpoints

    Meta-Analysis Co-primary Efficacy Endpoints • Nasal obstruction/congestion score • change from baseline to Day 90 by patients using questionnaires • Bilateral polyp grade • change from baseline to Day 90 by the independent, blinded panel Steroid releasing implant discussed is not approved by the FDA

  10. Slide 10: Well Balanced Baseline Characteristics

    Well Balanced Baseline Characteristics Treatment Control Total no. of subjects 254 146 Male 61.4% 59.6% Age (y) 49.9 ± 12.8 49.1 ± 12.7 Medical history: • Asthma 71.3% 63.0% • Allergic rhinitis 77.2% 79.5% • Aspirin exacerbated respiratory disease 16.1% 17.8% ESS history: • Number of prior ESS • 1 4

  11. Slide 11: Meta-Analysis Co-Primary Efficacy Endpoints

    Meta-Analysis Co-Primary Efficacy Endpoints Treatment Control Nasal obstruction/congestion score change from baseline to Day 90 N 252 143 Mean ± SD -0.95 ± 0.88 -0.68 ± 0.93 Between group difference (95% CI) -0.27 (-0.38, -0.04) P-value 0.0176 Bilateral polyp grade (panel) change from baseline to Da

  12. Slide 12: Endoscopic Outcomes by Clinical Investigators

    Endoscopic Outcomes by Clinical Investigators Bilateral Polyp Grade Ethmoid Sinus Obstruction Day 14 Day 30 Day 60 Day 90 Day 14 Day 30 Day 60 Day 90 0 0 -5 -0.5 Baseline Baseline -10 from from -1 Change -15 Change -20 -1.5 * * * -25 * * * * -30 -2 * Treatment Control * p-value < 0.0001 Steroid rele

  13. Slide 13: Reduction in Need for Revision ESS at Day 90 by Investigators

    Reduction in Need for Revision ESS at Day 90 by Investigators 0% -20% -32% -40% -59% -60% p-value < 0.0001 -80% -100% Treatment Control Steroid releasing implant discussed is not approved by the FDA. The product is an investigational drug not currently available for sale in the United States. The st

  14. Slide 14: Safety Results

    Safety Results • 1 (0.4%) device-related serious adverse event (epistaxis) • Similar incidence of adverse events between groups Steroid releasing implant discussed is not approved by the FDA. The product is an investigational drug not currently available for sale in the United States. The steroid re

  15. Slide 15: Conclusion

    Conclusion In-office placement of the corticosteroid-releasing implants in patients with recurrent nasal polyps resulted in reductions in: • clinical symptoms • polyp burden • the need for revision surgery Steroid releasing implant discussed is not approved by the FDA. The product is an investigatio

  16. Slide 16: Thank you!

    Thank you!

Intersect ENT — Technical Presentation (September 2017) on 6ix